The German model with an independent panel that examines and compares drugs is an excellent model that should be implemented not only in Germany but also in other countries. It’s quite surprising that Medicare/Medicaid are not implanting such a method. German tax payers should be appreciative of their medical sector that value their taxes and their patients for which it applies such measures.